2.68
price down icon7.59%   -0.22
after-market After Hours: 2.68
loading
Galecto Inc stock is traded at $2.68, with a volume of 158.91K. It is down -7.59% in the last 24 hours and down -21.64% over the past month. Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$2.90
Open:
$2.85
24h Volume:
158.91K
Relative Volume:
0.68
Market Cap:
$3.20M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-1.8483
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
+10.74%
1M Performance:
-21.64%
6M Performance:
-63.09%
1Y Performance:
-84.79%
1-Day Range:
Value
$2.59
$2.90
1-Week Range:
Value
$2.50
$3.2248
52-Week Range:
Value
$2.01
$18.50

Galecto Inc Stock (GLTO) Company Profile

Name
Name
Galecto Inc
Name
Phone
45-70-70-52-10
Name
Address
75 STATE STREET, BOSTON
Name
Employee
5
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
GLTO's Discussions on Twitter

Compare GLTO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLTO
Galecto Inc
2.68 3.20M 0 -38.35M -36.91M -1.45
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Galecto Inc Stock (GLTO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-26-21 Resumed Credit Suisse Outperform
Nov-23-20 Initiated BofA Securities Buy
Nov-23-20 Initiated Credit Suisse Outperform
Nov-23-20 Initiated SVB Leerink Outperform

Galecto Inc Stock (GLTO) Latest News

pulisher
Apr 16, 2025

Keppel DC REIT (OTCMKTS:KPDCF) Short Interest Up 133.4% in March - Defense World

Apr 16, 2025
pulisher
Apr 16, 2025

Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 133.6% in March - Defense World

Apr 16, 2025
pulisher
Apr 11, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - benzinga.com

Apr 11, 2025
pulisher
Apr 03, 2025

Galecto, Inc. Focuses on Oncology and Liver Diseases - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

GLTO stock touches 52-week low at $2.78 amid sharp annual decline - Investing.com UK

Apr 03, 2025
pulisher
Mar 27, 2025

Galecto stock hits 52-week low at $3.75 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Galecto stock hits 52-week low at $3.75 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

Galecto stock hits 52-week low at $4.39 amid market challenges - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON… - RTTNews

Mar 26, 2025
pulisher
Mar 25, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 25, 2025
pulisher
Mar 21, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Galecto (GLTO) Shares Rally Amid Positive Market Momentum - Stocks Telegraph

Mar 21, 2025
pulisher
Mar 20, 2025

Galecto Reports Full-Year 2024 Financial Results - The Manila Times

Mar 20, 2025
pulisher
Mar 19, 2025

Galecto Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Galecto, Inc. Completes Strategic Review, Acquires Global Rights to GB3226 for Oncology and Liver Disease Focus - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Galecto Cuts Losses by $17M, Acquires Promising AML Drug Candidate - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Galecto Inc expected to post a loss of $2.97 a shareEarnings Preview - TradingView

Mar 19, 2025
pulisher
Mar 14, 2025

Idiopathic Pulmonary Fibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight - The Globe and Mail

Mar 14, 2025
pulisher
Mar 12, 2025

Galecto stock plunges to 52-week low at $3.76 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 11, 2025

Galecto stock plunges to 52-week low at $3.76 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 07, 2025

Galecto (GLTO) Projected to Post Quarterly Earnings on Friday - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga

Mar 06, 2025
pulisher
Feb 28, 2025

Galecto stock hits 52-week low at $4.20 amid market challenges - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

Galecto stock hits 52-week low at $4.20 amid market challenges By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 15, 2025

Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World

Feb 15, 2025
pulisher
Feb 12, 2025

Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

Galecto to Participate in Upcoming Investor Conferences - The Globe and Mail

Feb 11, 2025
pulisher
Feb 11, 2025

Galecto stock hits 52-week low at $4.39 amid market challenges By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Estimates Galecto FY2024 Earnings - Defense World

Feb 11, 2025
pulisher
Feb 08, 2025

Brokers Set Expectations for Galecto FY2029 Earnings - Armenian Reporter

Feb 08, 2025
pulisher
Feb 06, 2025

Galecto to Participate in Upcoming Investor Conferences -February 06, 2025 at 08:01 am EST - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

Biotech Spotlight: Galecto Lines Up Triple Conference Showcase for Investors - StockTitan

Feb 06, 2025
pulisher
Feb 01, 2025

Where are the Opportunities in (GLTO) - Stock Traders Daily

Feb 01, 2025
pulisher
Jan 24, 2025

Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga

Jan 24, 2025
pulisher
Jan 23, 2025

Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

(GLTO) On The My Stocks Page - Stock Traders Daily

Jan 22, 2025
pulisher
Jan 13, 2025

Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World

Jan 13, 2025
pulisher
Jan 09, 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win - PharmaVoice

Jan 09, 2025
pulisher
Jan 07, 2025

Galecto CEO Hans T. Schambye sells $7,509 in shares - Investing.com

Jan 07, 2025

Galecto Inc Stock (GLTO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):